Effect Analysis of New Hypoglycemic Drugs in Combined Treatment of Type 2 Diabetes
Objective To analyze effect of Liraglutide in combined treatment of type 2 diabetes.Methods The paper chose 50 patients admitted to our hospital between January 2021 and December 2022 as study subjects,and divided them into two groups according to different treatment methods.Observation group was treated with liraglutide,while control group with pioglitazone metformin.Treatment effect between two groups was compared.Results There was no statistically significant difference in HbA1c and fasting blood glucose between two groups before treatment(P>0.05).After treatment,the HbA1c was(6.52±0.18)%and fasting blood glucose was(6.31±0.46)mmol/L in observation group,lower than(7.02±0.37)%and(6.62±2.27)mmol/L in control group,with statistical difference(P<0.05).There was no statistically significant difference in BMI between two groups before intervention(P>0.05).After treatment,BMI of observation group was(23.39±0.28)kg·m2,lower than(26.43±0.37)kg·m2 in control group,with statistical difference(P<0.05).Conclusion New type of hypoglycemic drug Liraglutide can improve blood glucose indicators of patients better than oral pioglitazone and metformin,which is beneficial for reducing weight of patients and is worth promoting.
Type 2 diabetesLiraglutidePioglitazone and metforminHbA1cFasting blood glucoseBMI
万方数据
维普
